Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice

Background Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease (1/500) and the most common cause of sudden cardiac death in young people. Pathogenic mutation detection of HCM is having a growing impact on the medical management of patients and their families. However, the remarkable genetic and allelic heterogeneity makes molecular analysis by conventional methods very time-consuming, expensive and difficult to realise in a routine diagnostic molecular laboratory. Method and results The authors used their custom DNA resequencing array which interrogates all possible single-nucleotide variants on both strands of all exons (n=160), splice sites and 5′-untranslated region of 12 HCM genes (27 000 nucleotides). The results for 122 unrelated patients with HCM are presented. Thirty-three known or novel potentially pathogenic heterozygous single-nucleotide variants were identified in 38 patients (31%) in genes MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL3 and ACTC1. Conclusions Although next-generation sequencing will replace all large-scale sequencing platforms for inherited cardiac disorders in the near future, this HCM resequencing array is currently the most rapid, cost-effective and reasonably efficient technology for first-tier mutation screening of HCM in clinical practice. Because of its design, the array is also an appropriate tool for initial screening of other inherited forms of cardiomyopathy.

[1]  A. Angelini,et al.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy , 2010, European heart journal.

[2]  J. Seidman,et al.  A novel custom resequencing array for dilated cardiomyopathy , 2010, Genetics in Medicine.

[3]  Eamonn Sheridan,et al.  Genetic diagnosis of familial breast cancer using clonal sequencing , 2010, Human mutation.

[4]  A. Kimura,et al.  Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond , 2010, Journal of Human Genetics.

[5]  H. Rehm,et al.  An Overview of Custom Array Sequencing , 2009, Current protocols in human genetics.

[6]  S. Antonarakis,et al.  A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy , 2008, Human mutation.

[7]  S. Poths,et al.  Array-Based Resequencing Assay for Mutations Causing Hypertrophic Cardiomyopathy , 2008, Clinical chemistry.

[8]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[9]  A. Tajik,et al.  Yield of genetic testing in hypertrophic cardiomyopathy. , 2005, Mayo Clinic proceedings.

[10]  Masahiko Hoshijima,et al.  Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[11]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[12]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[13]  V. Regitz-Zagrosek,et al.  The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.

[14]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[15]  O. Havndrup,et al.  Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. , 2003, Cardiovascular research.

[16]  P. Elliott,et al.  Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. , 2003, The Journal of clinical investigation.

[17]  H. Watkins,et al.  Mutations of the Light Meromyosin Domain of the &bgr;-Myosin Heavy Chain Rod in Hypertrophic Cardiomyopathy , 2002, Circulation research.

[18]  E. Fleck,et al.  Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[19]  H. Nishi,et al.  Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. , 2001, American heart journal.

[20]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[21]  J. Moolman-Smook,et al.  The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. , 1999, American journal of human genetics.

[22]  B. Hainque,et al.  Familial hypertrophic cardiomyopathy: from mutations to functional defects. , 1998, Circulation research.

[23]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[24]  M. Komajda,et al.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.

[25]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[26]  P. Rogan,et al.  A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. , 1994, Human molecular genetics.

[27]  C. Hengstenberg,et al.  Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. , 1993, The Journal of clinical investigation.

[28]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[29]  T. Hayashi,et al.  Molecular etiology of idiopathic cardiomyopathy in Asian populations. , 2001, Journal of cardiology.